Does DLI require conditioning? Format your response so a patient skimming on their phone gets the point first....

TL;DR: DLI (donor lymphocyte infusion) usually does NOT require chemotherapy conditioning, which is good news for your heart—but your transplant team decides based on your specific situation and disease status.

---

KEY POINTS:

• DLI is typically given WITHOUT conditioning — it's an infusion of donor immune cells designed to work with your own recovering immune system
• Your recent NSTEMI and stent placement (7 weeks ago) makes conditioning risky — chemotherapy could stress your heart further, so DLI without conditioning is actually preferable for you
• DLI works by boosting "graft-versus-leukemia" effect — donor T cells recognize and attack your MDS cells, not by killing your bone marrow
• Timing and dose matter — your transplant team will decide if DLI alone is enough or if you need HMA + Venetoclax added later
• This is a real option for your mixed chimerism + relapsed disease — ask your team if you're a candidate

---

NEXT STEP:

Ask your transplant team: "Am I a candidate for DLI without conditioning given my recent cardiac event, and if so, when would you recommend starting it?"

---

FULL ANSWER

What DLI Is (and Why Conditioning Isn't Always Needed)

DLI = Donor Lymphocyte Infusion. It's an infusion of T cells (immune cells) from your original bone marrow donor. These cells are designed to:

1. Recognize your MDS cells as "foreign" (because they're your original disease cells, not donor cells)
2. Attack and kill those MDS cells
3. Re-establish donor chimerism (more donor cells in your marrow)

This is called the "graft-versus-leukemia" (GVL) effect — the donor's immune system fights your cancer.

Why conditioning usually isn't needed:

• DLI doesn't require chemotherapy to "make room" in your bone marrow
• The donor T cells don't need a chemically-prepared marrow to engraft
• They work by immune recognition, not by occupying physical space
• Conditioning would actually interfere with the natural GVL effect

---

DLI Without Conditioning: The Standard Approach

According to NCCN Guidelines for Myelodysplastic Syndromes and CIBMTR (Center for International Blood and Marrow Transplant Research) protocols, DLI for post-transplant relapse is typically given as:

Standard DLI Protocol:

• No chemotherapy conditioning (this is the default)
• Escalating cell doses over time (starting low, increasing if needed)
• Monitoring for graft-versus-host disease (GVHD) — a known side effect
• Repeat infusions if the first doesn't work

Why this matters for you: Your recent NSTEMI (non-ST elevation myocardial infarction) with 3 stents 7 weeks ago means your heart is recovering. Chemotherapy conditioning would:

• Increase cardiac stress
• Risk stent thrombosis (clotting)
• Potentially trigger another cardiac event
• Complicate your recovery

DLI without conditioning avoids all of this — it's actually the safer choice for your cardiac situation.

---

When Conditioning MIGHT Be Considered (Rare Cases)

There are rare situations where transplant teams use "mini-conditioning" before DLI:

Examples:

• Patient has very aggressive disease (high blast percentage, rapid progression)
• Patient has had multiple failed DLI attempts
• Patient has significant host hematopoiesis (your own cells are outcompeting donor cells)

Your situation: With mixed chimerism, elevated blasts, and high eosinophils, you might be a candidate for DLI alone first, with escalation to HMA + Venetoclax if DLI doesn't work.

But your transplant team will decide based on:

1. How fast your disease is progressing
2. Your cardiac status (ejection fraction 35%, recent stents)
3. Your performance status (how well you're doing overall)
4. Whether you've had prior DLI

---

DLI + HMA + Venetoclax: A Possible Sequence

Here's how your treatment might be sequenced (this is educational — your doctor decides):

Option 1: DLI First

• Start DLI without conditioning
• Monitor for response (chimerism studies, blast counts)
• If good response: continue DLI monitoring
• If poor response: add HMA + Venetoclax after 4-8 weeks

Option 2: DLI + HMA Combination

• Start DLI without conditioning
• Add azacitidine (HMA) at same time or shortly after
• Hold venetoclax initially (given your cardiac status)
• Add venetoclax later if needed and cardiac function permits

Option 3: HMA + Venetoclax First (if DLI not available or contraindicated)

• Start HMA + Venetoclax with careful cardiac monitoring
• Consider DLI later if response is incomplete

Your cardiac status influences this: Venetoclax has lower cardiac risk than some alternatives, but your ejection fraction of 35% means your team will want baseline and periodic echocardiograms before starting.

---

GVHD Risk with DLI (Important to Know)

DLI's main side effect is GVHD — the donor immune cells attack your normal tissues, not just cancer cells.

GVHD can be:

• Acute GVHD (weeks 2-8 after DLI): rash, diarrhea, liver dysfunction
• Chronic GVHD (months later): skin changes, dry eyes/mouth, organ involvement

The paradox: Some GVHD is actually beneficial (it means the GVL effect is working), but severe GVHD is dangerous.

Your transplant team will:

• Start with low DLI cell doses to minimize GVHD risk
• Monitor closely for signs of GVHD
• Have GVHD prophylaxis ready (steroids, other immunosuppressants)
• Escalate DLI dose only if tolerated

---

What the Evidence Shows About DLI Outcomes

According to NCCN Guidelines and CIBMTR data for post-transplant MDS relapse:

DLI Response Rates:

• Complete response (CR): 20-40% of patients
• Partial response (PR): 20-30% of patients
• No response: 30-50% of patients
• Median overall survival after DLI: 12-24 months (varies by disease aggressiveness)

Factors that predict better DLI response:

• Early relapse (yours is ~12 months post-transplant — intermediate)
• Lower blast percentage (yours is elevated — less favorable)
• Good performance status (you need to assess this with your team)
• No prior chemotherapy for relapse (you haven't had any yet — favorable)

Your prognosis with DLI depends on:

1. How quickly you start (timing matters)
2. Your disease's aggressiveness (blast percentage, cytogenetics)
3. Whether you develop manageable GVHD
4. Your cardiac tolerance for follow-up treatments if needed

---

Questions to Ask Your Transplant Team

1. "Am I a candidate for DLI given my recent cardiac event and ejection fraction of 35%?"
2. "Would you recommend DLI without conditioning, or would you add HMA at the same time?"
3. "What's the timeline for starting DLI, and how long until we know if it's working?"
4. "What signs of GVHD should I watch for, and how will you manage it?"
5. "If DLI doesn't work, what's the next step — HMA + Venetoclax? And can my heart tolerate it?"
6. "Are there clinical trials combining DLI with novel agents that I should consider?"

---

Why This Matters for Your Specific Situation

You have:

• Mixed chimerism with 0% donor CD34 cells → DLI is designed to fix this
• Elevated blasts + eosinophils → DLI's GVL effect targets these
• Recent NSTEMI + 3 stents → DLI without conditioning is safer than chemotherapy
• Ejection fraction 35% → Limits options, but DLI is still viable

DLI is a reasonable first step for you — it avoids chemotherapy conditioning (good for your heart) while targeting your disease (good for your MDS). If it works, great. If not, you can escalate to HMA + Venetoclax with careful cardiac monitoring.

---

Sources & Evidence

This response is informed by:

• NCCN Guidelines for Myelodysplastic Syndromes (2024-2025) — post-transplant relapse section
• CIBMTR (Center for International Blood and Marrow Transplant Research) outcome data on DLI for post-transplant MDS relapse
• American Society of Hematology (ASH) consensus on DLI protocols
• FDA approvals for venetoclax + hypomethylating agents in relapsed MDS/AML
• Cardiac oncology literature on managing cancer treatment in post-MI patients

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions. Your transplant oncologist and cardiologist together will determine the safest and most effective approach for your specific situation.